Kelley Shannon T sold $431K of MDGL
Kelley Shannon T (General Counsel) sold 1,077 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $400.00 ($0.43M total) on 2026-11-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing provides a fresh, primary source of insider activity, but the transaction size is modest relative to the company's market cap.
Market read
A small insider sell by a senior officer; likely limited price impact.
What to watch
Potential upcoming clinical data or regulatory events could outweigh the impact of this modest insider sale.
Background
SEC Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.
Ticker impact
General Counsel Kelley Shannon T sold 1,077 shares of Madrigal Pharmaceuticals for $430,800 via a 10b5‑1 plan, reducing her holdings to 10,397 shares.
likely slight downward pressure as the market prices in the insider sell
A $430k sale by a senior officer is a primary disclosure but modest in scale; traders may view it as a minor bearish signal.
Market effects
Minimal impact on the biotech sector; insider sales are routine.
No broader regional effect.
Limited to Madrigal shareholders.
Counterpoint
The sale could be unrelated to company fundamentals and may not affect price.
Key entities
- companyMadrigal Pharmaceuticals, Inc.
Biotech firm developing therapies for rare diseases.
- personKelley Shannon T
General Counsel and officer at Madrigal.
